TG Therapeutics Completes Enrollment for Subcutaneous BRIUMVI Phase 3 Trial; Top-Line Data Expected Late 2026
TGTX sits 36% above its 52-week low of $25.28.
Summary
TG Therapeutics has announced the completion of enrollment for its Phase 3 trial evaluating a subcutaneous formulation of BRIUMVI for relapsing forms of multiple sclerosis. This is a significant development as BRIUMVI is currently approved as an intravenous infusion, and a subcutaneous option could offer greater patient flexibility, including potential self-administration at home. This advancement could materially broaden the market reach and competitive positioning of the company's key product, building on the strong BRIUMVI sales reported in the recent 10-K. Investors should now watch for the top-line data from this trial, which is anticipated around year-end 2026 or early 2027.
At the time of this announcement, TGTX was trading at $34.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $25.28 to $46.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.